NCT02231710View on ClinicalTrials.gov

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

January 31, 2018

Conditions
Primary Immune Deficiency DisordersHemophagocytic LymphohistiocytosisInherited Bone Marrow Failure SyndromeHemoglobinopathiesMetabolic Disorders
Interventions
BIOLOGICAL

BPX-501 and Rimiducid

Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7

Trial Locations (1)

98109

Fred Hutchinson Cancer ResearchCenter, Seattle

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY